Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lopinavir/ Ritonavir
DRUG
2 trials
Sponsors
University College, London
, October 6 University
Conditions
COVID-19
Covid19
Pneumonia
Phase 2
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
Completed
NCT04499677
University College, London
COVID-19
Start: 2020-09-24
End: 2022-01-17
Updated: 2022-12-15
Phase 4
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT04779047
October 6 University
Covid19, Pneumonia
Start: 2020-10-01
End: 2021-04-05
Target: 150
Updated: 2021-03-17
Related Papers
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
PLoS Medicine
2022-10-19
31 citations
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
2021-11-02
27 citations
Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial.
2021-07-28
12 citations
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
2021-03-08
12 citations